Lumos Diagnostics Holdings (ASX:LDX) said it will start receiving Medicare reimbursement for its FebriDx rapid diagnostic test designed to distinguish bacterial from viral respiratory infections in two US regions, according to a Thursday filing with the Australian bourse.
Effective this month, the test has been included in the Medicare fee schedule in the Palmetto and Novitas regions at a rate of $41.38 per test, the filing said.
The test is reimbursable in both moderately complex and clinical laboratory improvement amendments waived settings, the company said.
Shares of the company rose about 14% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.